Segment Results (Schedule Of Reconciliations Of Consolidated Adjusted Income (Loss) Before Income Tax) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting Information [Line Items]
Total consolidated loss from continuing operations before income tax	$ (753,500)	$ (165,465)	$ (930,851)	$ (372,943)
Interest expense, net	121,747	111,919	233,746	228,712
Amortization of intangible assets	191,000	212,800	454,077	424,500
Asset impairment charges	725,044	39,951	929,006	169,576
Acquisition-related and integration items	4,190	48,171	15,070	60,725
Loss on extinguishment of debt	51,734	0	51,734	0
Severance costs	700	8,400	21,500	15,200
Transaction costs	2,200	24,300	6,900	47,500
Change in fair value of contingent consideration	2,000	23,900	8,134	13,204
Inventory Write-Offs
Segment Reporting Information [Line Items]
Restructuring expenses	7,900
Other Restructuring Costs
Segment Reporting Information [Line Items]
Restructuring expenses	16,000	7,100	17,500	11,800
Segment Reconciling Items
Segment Reporting Information [Line Items]
Corporate unallocated costs	34,152	49,818	81,620	86,098
Amortization of intangible assets	190,943	212,844	454,077	424,513
Inventory step-up and certain manufacturing costs that will be eliminated pursuant to integration plans	100	29,103	215	97,579
Upfront and milestone payments to partners	3,082	2,688	6,177	4,105
Separation benefits and other cost reduction initiatives	24,614	22,174	47,284	60,630
Impact of VOLTAREN® Gel generic competition	0	0	0	(7,750)
Certain litigation-related and other contingencies, net	(2,600)	5,259	(1,664)	10,459
Asset impairment charges	725,044	39,951	929,006	169,576
Acquisition-related and integration items	4,190	48,171	15,070	60,725
Loss on extinguishment of debt	51,734	0	51,734	0
Foreign currency impact related to the remeasurement of intercompany debt instruments	(3,233)	417	(5,927)	1,672
Other, net	0	1,124	1,759	(3,070)
Operating Segments
Segment Reporting Information [Line Items]
Total consolidated loss from continuing operations before income tax	$ 396,273	358,003	882,246	760,306
2016 US Generic Pharmaceuticals Restructuring
Segment Reporting Information [Line Items]
Restructuring expenses			$ 1,117
2016 US Generic Pharmaceuticals Restructuring | Inventory Write-Offs
Segment Reporting Information [Line Items]
Restructuring expenses		$ 6,400		$ 33,300